ReviewCurrent rheumatology reports2016
Emerging Therapies in Antiphospholipid Syndrome.
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations.Frontiers in immunology · 2019Trial
- Methodology of the development of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS).EULAR rheumatology open · 2026Article
- Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances.Rheumatology international · 2025Review
- Whole transcriptome analysis and preliminary construction of ceRNA networks in obstetric antiphospholipid syndrome.Frontiers in immunology · 2025Article
- Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus.Biomedicines · 2024Article
- Prevalence, risk factors, and prognosis of central nervous system manifestations in antiphospholipid syndrome.Scientific reports · 2023Article
- Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre.Journal of clinical medicine · 2023Article
- An Update on Antiphospholipid Syndrome.Current rheumatology reports · 2022Review
- Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012-2021).Frontiers in pharmacology · 2022Article
- Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin.Clinical rheumatology · 2021Review
- Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers.Biomedicines · 2021Review
- The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?Pharmacological research · 2020Review
- Management of Non-criteria Manifestations in Antiphospholipid Syndrome.Current rheumatology reports · 2020Review
- EULAR recommendations for the management of antiphospholipid syndrome in adults.Annals of the rheumatic diseases · 2019Article
- Silent Myocardial Perfusion Abnormalities Detected by Stress Cardiovascular Magnetic Resonance in Antiphospholipid Syndrome: A Case-Control Study.Journal of clinical medicine · 2019Article
- Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.Frontiers in neurology · 2018Review
- Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.Frontiers in immunology · 2017Review
- Prevention of thrombosis in antiphospholipid syndrome.Hematology. American Society of Hematology. Education Program · 2016Review
- Defibrotide in the treatment of hepatic veno-occlusive disease.Hepatic medicine : evidence and research · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by arterial and venous thromboses and pregnancy morbidity in the presence of antiphospholipid antibodies. Although warfarin remains the main therapeutic choice in APS, there is still concern about its efficacy, safety, and patient compliance. Patients with refractory APS to conventional therapy as well as patients with non-classical manifestations of APS may have alternative treatment approaches. APS pathogenesis has been further elucidated over the past years identifying new molecules as potential new treatment targets. This review summarizes available data from in vitro and animal models and clinical studies on the role of new potential treatment approaches including new oral anticoagulants and immunoregulatory agents: direct thrombin or factor Xa inhibitors, hydroxychloroquine, statins, B cell inhibition, complement inhibition, peptide therapy, nuclear factor κB and p38 mitogen-activated kinase inhibitors, defibrotide, abciximab, mTOR inhibitor, and other potential targets. Large multicenter prospective studies of well-characterized APS patients are needed to assess the efficacy and safety profile of these potential treatment alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.